Abstract:Abstract Background. By SNP genotyping and RNA sequencing of 471 normal prostate samples, we recently created a prostate tissue-based eQTL dataset and identified significant eQTL signals at 51 prostate cancer risk loci. To functionally characterize these risk SNPs, we developed a massively parallel sequencing technology to screen SNPs for their allele-dependent protein binding differences. We combined this technology (called SNPs-seq) with another high throughput assay (called STARR-seq) to screen the risk loci with significant prostate-specific eQTL signals. Methods. To select candidate functional SNPs in eQTL regions, we took advantage of existing epigenomic datasets and available tools including ENCODE, HaploReg, and Regulome. For all selected SNPs, we first made allele-specific double-strand oligos and performed DNA-protein binding assays. We then performed sequencing analysis on the protein-bound DNA oligos and determined allele-specific protein binding differences. To evaluate reproducibility of SNPs-seq, we performed each assay in duplicates. We cloned SNPs-seq screened SNP regions showing allele-specific protein binding differences into the STARR-seq vector to further determine allele-specific enhancer activities. Finally, we performed EMSA and luciferase reporter assays to validate a set of promising candidate SNPs. Results. From 51 risk loci with strong eQTL signals, we selected 374 SNPs with strong indication of regulatory potential, as evidenced by overlapping with epigenomic marks. When comparing technical duplicates, sequence read counts from the SNPs-seq showed significant correlation with r2>=0.99. By normalizing input controls, we found 101 of the 374 SNPs showing significant allelic protein binding differences (>=1.5-fold binding difference between variant and reference alleles). Interestingly, three published functional SNPs (rs12769019, rs10993994, and rs4907792) were also among the significant SNPs, validating SNPs-seq as functional SNP screening tool. To further validate the candidate SNPs from SNPs-seq, we applied STARR-seq and tested the 101 SNPs-containing sequences (371-686bp) in LNCaP cell line under androgen treatment. This analysis revealed 11 SNPs that not only demonstrated enhancer/repressor activity but also functioned with allelic differences. EMSA and luciferase reporter assays confirmed 6 SNPs with allele-dependent enhancer/repressor activity. Conclusions. We developed a high throughput sequencing-based technology to screen large number candidate SNPs for their allelic protein binding differences. The SNPs-seq coupled with STARR-seq will provide a powerful strategy for functionally characterizing risk loci in prostate cancer and other common diseases. Further understanding genetic role of prostate cancer etiology may facilitate the translation of population-based discovery into biological mechanisms and eventually benefit clinical practice. Citation Format: Peng Zhang, Jing Zhu, Sufyan Suleman, Yong-Chen Guo, Mei-Jun Du, Li-Dong Wang, Gong-Hong Wei, Liang Wang. Functional characterization of prostate cancer risk loci by SNPs-seq and STARR-seq [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 1280. doi:10.1158/1538-7445.AM2017-1280

High-throughput Screening of Prostate Cancer Risk Loci by Single Nucleotide Polymorphisms Sequencing.

Abstract 1280: Functional Characterization of Prostate Cancer Risk Loci by SNPs-seq and STARR-seq

A Genetic Study and Meta-Analysis of the Genetic Predisposition of Prostate Cancer in a Chinese Population

Combined SNPs Sequencing and Allele Specific Proteomics Capture Reveal Functional Causality Underpinning the 2p25 Prostate Cancer Susceptibility Locus

Optimized high-throughput screening of non-coding variants identified from genome-wide association studies

Chromatin Interactions and Candidate Genes at Ten Prostate Cancer Risk Loci.

Systematic Enrichment Analysis of Potentially Functional Regions for 103 Prostate Cancer Risk-Associated Loci

Identification and validation of regulatory SNPs that modulate transcription factor chromatin binding and gene expression in prostate cancer

Post genome-wide association studies functional characterization of prostate cancer risk loci

A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer

High-throughput single-nucleotide polymorphisms genotyping: TaqMan assay and pyrosequencing assay.

Combined analysis with copy number variation identifies risk loci in lung cancer.

Systematic identification of regulatory variants associated with cancer risk

Parallel Reporter Assays Identify Altered Regulatory Role of Rs684232 in Leading to Prostate Cancer Predisposition.

A Sequential Methodology for the Rapid Identification and Characterization of Breast Cancer-Associated Functional SNPs.

A transcriptome-wide association study identifies novel candidate susceptibility genes for prostate cancer risk

Precise diagnosis of three top cancers using dbGaP data

Association of Prostate Cancer Risk with SNPs in Regions Containing Androgen Receptor Binding Sites Captured by ChIP-On-chip Analyses.

Pathway Analysis of Genome-Wide Association Study on Serum Prostate-Specific Antigen Levels

Modulation of Long Noncoding RNAs by Risk SNPs Underlying Genetic Predispositions to Prostate Cancer.

Predictive performance of prostate cancer risk in Chinese men using 33 reported prostate cancer risk-associated SNPs.